【百济神州:美国FDA批准百泽安®联合方案用于HER2阳性胃食管腺癌一线治疗】 百济神州宣布美国食品药品监督管理局已批准百泽安®的新增适应症上市许可申请,即与百赫安®与化疗联合,用于局部晚期不可切除或转移性HER2阳性胃、胃食管结合部或食管腺癌成人患者的一线治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.